Enlivex Ltd.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Non-accelerated filer
State of Incorporation
Israel
Country
Israel
Business Address
37 DEREH MENACHEM BEGIN ST., TEL AVIV, ,
Mailing Address
37 DEREH MENACHEM BEGIN ST., TEL AVIV, ,
Phone
972 (0) 3 7326616
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
$1.24B
Net Income
$2.33B
Total Assets
$392.05M
Total Liabilities
$3.30M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | April 8, 2026 | View on SEC |
| 6-K Foreign company current report | March 26, 2026 | View on SEC |
| 20-F Foreign company annual report | March 25, 2026 | View on SEC |
| 6-K Foreign company current report | March 25, 2026 | View on SEC |
| 6-K Foreign company current report | March 24, 2026 | View on SEC |
| 6-K Foreign company current report | March 23, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
| 3 Initial insider ownership report | March 18, 2026 | View on SEC |
Annual Reports
20-F
March 25, 2026
- Developing Allocetra™, a novel cell therapy for life-threatening inflammation.
- Pioneering a 'digital treasury' strategy by holding corporate reserves in RAIN cryptocurrency.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.